01
Overview
💊 Targeting Intractable Drivers: KRAS mutations previously resisted conventional screening.
Picomolar Binding
De novo structure achieves -78% tumor volume regression in vivo.
02
Oncology Drug Discovery (Before ➔ Now)
Было: Multi-year random screening of millions of small chemical compounds ➔ Стало: De novo algorithmic synthesis of tailored inhibitors within 46 days
Было: Systemic chemotherapy toxicity due to non-specific cellular targets ➔ Стало: Picomolar selectivity tailored strictly to oncogenic mutational pocket
03
Overview
Synthesis Time: 46 days de novo
Tumor Inhibition: -78% volume in vivo
Target: KRAS G12D oncogene
Binding Affinity: Picomolar (KD < 50 pM)
30 seconds
Key facts
Leveraging geometric diffusion models, researchers engineered an alpha-helical microprotein targeting oncogenic KRAS G12D in non-small cell lung cancer within 46 days.
- Leveraging geometric diffusion models, researchers engineered an alpha-helical microprotein targeting oncogenic KRAS G12D in non-small cell lung cancer within 46 days.
Want to go deeper?
The Hook & Core Paradox
De Novo AI Pharmacology: What happens when an algorithm designs a clinical-grade drug candidate in 45 days?
Between the Lines (Market & Margin Shift)
Compressing pharmaceutical pipelines: transforming a multi-year screening lottery into deterministic generative design.
The Bottleneck (Physical & Engineering Barrier)
In-vivo biological unpredictability: unforeseen off-target metabolic toxicity despite near-perfect in-silico binding.
3–5 Year Horizon (Structural Shift)
Personalized onco-therapeutics: automated synthesis of patient-specific small molecules within weeks of biopsy.
Chronicle: Past 5 Years
2024–2025
Initial research phase and prototype validation.
2026
Production deployment and commercial integration.
Forecast Scenarios
3 Years
Ecosystem consolidation and protocol standardization.
5 Years
Ubiquitous deployment across operational platforms.
10 Years
Foundation for next-generation autonomous systems.